研究等業績 - その他 - 成田　伸太郎

転移性去勢感受性・抵抗性前立腺癌に対するアビラテロン投与患者における薬物血中濃度と臨床因子の関連検討(Pharmacogenomic features on clinical outcomes in patients with castration-sensitive and -resistant prostate cancer who received abiraterone acetate)

高橋 佳子, 成田 伸太郎, 塩田 正己, 三浦 昌朋, 加賀谷 英彰, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 沼倉 一幸, 齋藤 満, 江藤 正俊, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   PP54 - 07   2023年04月

進行性腎細胞癌に対する免疫チェックポイント阻害薬の治療効果を予測する血液・病理学的マーカーの探索(Exploring predictive blood and pathological markers for the efficacy of immune checkpoint inhibitors in advanced renal cell carcinoma)

蘇武 竜太, 嘉島 相輝, 小林 瑞貴, 山本 竜平, 奈良 健平, 沼倉 一幸, 齋藤 満, 成田 伸太郎, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   np13 - np13   2023年04月

進行性腎細胞癌に対する免疫チェックポイント阻害薬の治療効果を予測する血液・病理学的マーカーの探索(Exploring predictive blood and pathological markers for the efficacy of immune checkpoint inhibitors in advanced renal cell carcinoma)

蘇武 竜太, 嘉島 相輝, 小林 瑞貴, 山本 竜平, 奈良 健平, 沼倉 一幸, 齋藤 満, 成田 伸太郎, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   PP65 - 02   2023年04月

高リスク限局性前立腺癌患者における前立腺全摘除後の予後予測バイオマーカーとしての腫瘍浸潤CD8/FoxP3陽性細胞の有用性(Impact of tumor-infiltrating CD8+ and FoxP3+ lymphocytes expression in high-risk localized prostate cancer)

佐藤 博美, 成田 伸太郎, 高橋 佳子, 石田 雅宣, 小林 瑞貴, 嘉島 相輝, 山本 竜平, 奈良 健平, 沼倉 一幸, 齋藤 満, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   PP62 - 05   2023年04月

BRAF V600E変異は副腎腫瘍からのコルチゾール産生を亢進する(BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma)

沼倉 一幸, 武藤 弓奈, 杉山 志子, 小林 瑞貴, 関根 悠哉, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 齋藤 満, 成田 伸太郎, 西本 紘嗣郎, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   AOP08 - 03   2023年04月

代用膀胱造設術後23年で生じた代用膀胱内小腸癌の1例

船越 佑大, 嘉島 相輝, 関根 悠哉, 小林 瑞貴, 山本 竜平, 奈良 健平, 沼倉 一幸, 齋藤 満, 成田 伸太郎, 羽渕 友則, 南條 博

泌尿器外科 ( 医学図書出版(株) )  36 ( 4 ) 357 - 357   2023年04月

日本人上部尿路上皮癌の大規模ゲノム解析(Large-scale genetic analysis of Upper Urinary Tract Urothelial Carcinoma in Japanese)

関根 悠哉, 岩崎 雄介, 遠藤 ミキ子, 佐野 剛視, 赤松 秀輔, 小林 恭, 中川 英刀, 沼倉 一幸, 成田 伸太郎, 桃沢 幸秀, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   AOP06 - 07   2023年04月

Predictor of adverse pathology in patients who underwent deferred radical prostatectomy following active surveillance: Results from multi-institutional prospective observational cohort in the PRIAS-JAPAN.

Yoichiro Tohi, Ryou Ishikawa, Takuma Kato, Jimpei Miyakawa, Ryuji Matsumoto, Keiichiro Mori, Koji Mitsuzuka, Junichi Inokuchi, Masafumi Matsumura, Kenichiro Shiga, Hirohito Naito, Yasuo Kohjimoto, Norihiko Kawamura, Masaharu Inoue, Shusuke Akamatsu, Naoki Terada, Yoshiyuki Miyazawa, Shintaro Narita, Reiji Haba, Mikio Sugimoto

JOURNAL OF CLINICAL ONCOLOGY   41   2023年02月

研究発表要旨（国際会議）  

BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report.

Keisuke Okubo, Shintaro Narita, Atsushi Koizumi, Yoshiko Takahashi, Ryuichiro Sagehashi, Kanami Mori, Ryuta Sobu, Hiromi Sato, Soki Kashima, Mizuki Kobayashi, Ryohei Yamamoto, Taketoshi Nara, Kazuyuki Numakura, Mitsuru Saito, Hiroshi Nanjo, Tomonori Habuchi

Case reports in oncology   16 ( 1 ) 621 - 627   2023年

A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone metastasis were observed. The patient was referred to our hospital because of biochemical and radiographic progression after four cycles of docetaxel as a first-line therapy for castration-resistant prostate cancer. Transurethral resection of the prostate and hepatic biopsy revealed small-cell carcinoma with positive expression of neuroendocrine markers. The FoundationOne CDx next-generation sequencing test revealed several pathogenic variants, including BRCA2 (W1692fs*3), KEAP1 (R320W), and TP53 (C2385) mutation. After four cycles of chemotherapy with carboplatin plus etoposide (CE), the metastatic regions regressed markedly. The prostate-specific antigen (PSA) and neuron-specific enolase (NSE) level decreased by 96.9% and 91.6%, respectively. However, 2 months after the completion of four cycles of CE, elevation of tumor marker levels, and re-growth of the metastatic regions were observed. Although olaparib, a poly (ADP-ribose) polymerase inhibitor (PARPi), achieved a 45.2% decrease in NSE, the patient rejected to continue therapy because of G2 adverse events. After receiving an additional two cycles of CE and one cycle of cabazitaxel, the patient died because of cancer progression 24 months after the initial treatment for prostate cancer. Here, we present a case of BRCA2-altered small-cell neuroendocrine prostate cancer treated with both platinum-containing chemotherapy and PARPi. Both therapies achieved an initial response; however, durable responses were not obtained. Additional discussion regarding the optimal treatment strategy for BRCA-altered small-cell/neuroendocrine prostate cancer is required.

DOI PubMed

プロテインC活性低下を伴う免疫学的ハイリスク症例に対し生体腎移植を施行した1例

降幡研吾, 齋藤満, 青山有, 高橋佳子, 関根悠哉, 提箸隆一郎, 小林瑞貴, 嘉島相輝, 山本竜平, 奈良健平, 沼倉一幸, 成田伸太郎, 羽渕友則

秋田腎不全研究会誌(Web)   26   2023年

J-GLOBAL

プロテインC活性低下を伴う免疫学的ハイリスク症例に対し生体腎移植を施行した1例

降幡研吾, 齋藤満, 青山有, 高橋佳子, 関根悠哉, 提箸隆一郎, 小林瑞貴, 嘉島相輝, 山本竜平, 奈良健平, 沼倉一幸, 成田伸太郎, 羽渕友則

東北腎不全研究会プログラム・抄録集   49th   2023年

J-GLOBAL

当科における進行性尿路上皮癌に対するEnfortumab Vedotinの初期使用成績

加藤大, 小林瑞貴, 沼倉一幸, 関根悠哉, 提箸隆一郎, 武藤弓奈, 佐藤博美, 嘉島相輝, 山本竜平, 奈良健平, 齋藤満, 成田伸太郎, 羽渕友則

日本泌尿器科学会東部総会プログラム・抄録集   88th (CD-ROM)   2023年

J-GLOBAL

Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon’s experience

Numakura K.

World Journal of Surgical Oncology ( World Journal of Surgical Oncology )  20 ( 1 ) 202 - 202   2022年12月

INTRODUCTION: Warm ischemia time (WIT) is a primary concern for robot-assisted laparoscopic partial nephrectomy (RALPN) patients because longer WIT is significantly associated with postoperative deteriorating kidney function. Tumor complexity, determined by the RENAL nephrometry score (RENAL score), can help predict surgical outcomes, but it is unclear what RENAL score and clinical factors affect WIT. This study explored the clinical factors predicting long WIT in experienced surgeon to RALPN. MATERIALS AND METHODS: In our institute, 174 RALPNs were performed between November 2013 and February 2021, of which 114 were performed by a single surgeon and included in this study. Clinical staging and the total RENAL score were determined based on preoperative CT scans. The cases were divided into three groups based on experience: period 1: 1-38, period 2: 39-76, and period 3: 77-114. The clinical factors associated with longer WIT were analyzed per period. RESULTS: The overall median tumor diameter was 32 mm, and one patient had a positive surgical margin, but there were no cancer-related deaths. In total, there were 18 complications (15.8%). Periods 2 and 3 had larger tumor diameters (p < 0.01) and worse preoperative kidney function (p = 0.029) than period 1. A RENAL L-component score of 3 was associated with longer WIT in period 3 (odds ratio: 3.900; 95% confidence interval: 1.004-15.276; p = 0.044), but the tumor diameter and the total RENAL score were not. CONCLUSIONS: A large tumor in the central lesion indicated by the RENAL L-component score was associated with increased WIT in RALPN.

DOI PubMed

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer

Kimura H.

British Journal of Cancer ( British Journal of Cancer )  127 ( 9 ) 1680 - 1690   2022年11月

BACKGROUND: The prognostic significance of germline variants in homologous recombination repair genes in advanced prostate cancer (PCa), especially with regard to hormonal therapy, remains controversial. METHODS: Germline DNA from 549 Japanese men with metastatic and/or castration-resistant PCa was sequenced for 27 cancer-predisposing genes. The associations between pathogenic variants and clinical outcomes were examined. Further, for comparison, DNA from prostate biopsy tissue samples from 80 independent patients with metastatic PCa were analysed. RESULTS: Forty-four (8%) patients carried germline pathogenic variants in one of the analysed genes. BRCA2 was most frequently altered (n = 19), followed by HOXB13 (n = 9), PALB2 (n = 5) and ATM (n = 5). Further, the BRCA1, BRCA2, PALB2 and ATM variants showed significant association with a short time to castration resistance and overall survival (hazard ratio = 1.99 and 2.36; 95% CI, 1.15-3.44 and 1.23-4.51, respectively), independent of other clinical variables. Based on log-rank tests, the time to castration resistance was also significantly short in patients with BRCA1, BRCA2, PALB2 or ATM somatic mutations and TP53 mutations. CONCLUSIONS: Germline variants in BRCA1, BRCA2, PALB2 or ATM are independent prognostic factors of the short duration of response to hormonal therapy in advanced PCa.

DOI PubMed

Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy

Narita S.

International Journal of Urology ( International Journal of Urology )  29 ( 10 ) 1147 - 1154   2022年10月

OBJECTIVE: This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy. METHODS: The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into <75, 75-79, and ≥80 age groups. Propensity score matching was conducted to assess the cancer-specific survival of the groups. The 5-year net overall survival of each group was derived to evaluate relative survival compared with the general population using the Pohar-Perme estimator and the 2019 Japan Life Table. RESULTS: During the follow-up (median, 34 months), 1014 patients died, of which 807 died from metastatic prostate cancer progression. Compared with the <75 group, the cancer-specific survival of the 75-79 group was similar (hazard ratio 1.07; 95% confidence interval 0.84-1.37; P = 0.580), whereas that of the ≥80 group was significantly worse (hazard ratio 1.41; 95% confidence interval 1.10-1.80; P = 0.006). The 5-year net overall survival of the <75, 75-79, and ≥80 age groups were 0.678, 0761, and 0.718, respectively. The 5-year net overall survival of patients aged ≥80 years with low- and high-volume disease were 0.893 and 0.586, respectively, which was comparable with those in patients aged <75 years (0.872 and 0.586, respectively). CONCLUSIONS: Older metastatic prostate cancer patients aged ≥80 years had poorer cancer-specific survival compared with younger patients. Conversely, 5-year net overall survival in older patients aged ≥80 years was comparable with that in younger patients aged <75 years.

DOI PubMed

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer

Yanagisawa T.

Prostate ( Prostate )  82 ( 14 ) 1322 - 1330   2022年10月

BACKGROUND: Docetaxel-related adverse events (AEs) such as neutropenia and febrile neutropenia (FN) can be life-threatening. A previous in vivo study raised the hypothesis that the castration status affects the rate of hematologic AEs. We aimed to investigate the impact of castration status on the incidence of docetaxel-related AE in metastatic prostate cancer (mPCa) patients. METHODS: We retrospectively analyzed the records of 265 mPCa patients treated with docetaxel, comprising 92 patients with metastatic hormone-sensitive prostate cancer (mHSPC) and 173 patients with metastatic castration-resistant prostate cancer (mCRPC) between January 2015 and December 2021. Common terminology Criteria for Adverse Events (CTCAE) was applied to evaluate AEs. We analyzed the differential incidences between mHSPC and mCRPC, and risk factors of hematologic and nonhematologic AEs using a logistic regression model. RESULTS: The rate of patients who received primary prophylaxis against neutropenia was higher in those with the mHSPC compared with those with the mCRPC (7.5% vs. 33%, p < 0.001). Among the patients without primary prophylaxis, incidence rates of severe neutropenia (CTCAE ≥ Grade3) and FN were 89% and 16% in patients with mCRPC compared to 81% and 18% in those with mHSPC. Logistic regression analysis revealed that age ≥ 75 years and failure to provide primary prophylaxis were independent risk factors of severe neutropenia (odds ratio [OR]: 2.39, 95% confidential interval [CI]: 1.10-5.18 and OR: 15.8, 95% CI: 7.23-34.6, respectively). Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≧ 1 was an independent risk factor of FN (OR: 2.26, 95% CI: 1.13-4.54). Castration status (mHSPC vs. mCRPC) was not associated with the risks of severe neutropenia and FN. CONCLUSIONS: Castration status did not affect the risk of severe neutropenia or FN in mPCa patients treated with docetaxel regardless of the disease state. Failure to provide primary prophylaxis and advanced patient age are independent risk factors of severe neutropenia; while patients with poor PS are more likely to develop FN. These findings may help guide the clinical decision-making for proper candidate selection of docetaxel treatment.

DOI PubMed

特集 限局性前立腺癌診療バイブル-このへんでキッチリと前立腺癌診療の"あたりまえ"を整理しよう! 〈高齢者・その他〉 高齢者限局性前立腺癌治療

成田 伸太郎

臨床泌尿器科 ( 株式会社医学書院 )  76 ( 11 ) 844 - 850   2022年10月

DOI CiNii Research

ADT単独またはupfront治療を受けた去勢感受性転移性前立腺癌患者の健康関連QOL

石田 雅宣, 成田 伸太郎, 畠山 真吾, 米田 真也, 千葉 修治, 小泉 淳, 岡根 克己, 石田 俊哉, 堀川 洋平, 熊澤 光明, 秋濱 晋, 下田 次郎, 鈴木 丈博, 大山 力, 羽渕 友則

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  60回   P95 - 6   2022年10月

本邦における転移性去勢感受性前立腺癌患者に対するup-front治療の有用性

佐藤 博美, 成田 伸太郎, 木村 高弘, 畠山 真吾, 畠 憲一, 柳澤 孝文, 岡根 克己, 石田 俊哉, 堀川 洋平, 熊沢 光明, 下田 次郎, 鈴木 丈博, 大山 力, 頴川 晋, 羽渕 友則

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  60回   YOA O39 - 4   2022年10月

転移性腎癌におけるイピリムマブ・ニボルマブ併用療法の早期の耐性化と関連因子の検討

武藤 弓奈, 沼倉 一幸, 畠山 真吾, 関根 悠哉, 小林 瑞貴, 嘉島 相輝, 山本 竜平, 奈良 健平, 齋藤 満, 成田 伸太郎, 大山 力, 羽渕 友則

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  60回   P51 - 1   2022年10月